DAIC

DECEMBER 5, 2024

This funding will allow us to expand our commercial reach, which is especially germane following our recent achievements in attaining Medicare coverage and a CPT Category I code for advanced plaque analysis. Until Cleerly, healthcare providers have had no way to easily and completely assess plaque burden in a non-invasive manner.

Coronary Artery Disease 52

Coronary Artery Disease Medicare Technology Plaque 52

DAIC

JUNE 18, 2024

The breakthrough designation, according to the Milpitas, CA-based technology company, is for an indication to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. of the U.S. population.

Coronary Artery Disease 105

Coronary Artery Disease Technology Stent Stents 105

DAIC

MAY 8, 2024

Longitudinal assessment of safety of FEMOROPOPLITEAL endovascular treatment with paclitaxel-coated devices among Medicare beneficiaries.” Journal of Vascular Surgery Cases, Innovations and Techniques, vol. European Journal of Vascular and Endovascular Surgery, vol. 301–302, [link]. 3 Secemsky, Eric A., JAMA Internal Medicine, vol.

Coronary Artery Disease 111

Coronary Artery Disease Chest Pain Ischemia Myocardial Infarction 111

DAIC

JANUARY 3, 2024

3 HeartFlow’s FFR CT Analysis is covered by Medicare and for >99% of commercially insured lives. We've experienced a year of notable accomplishments and growth including the expansion of our product portfolio with Plaque Analysis and RoadMap Analysis. said John Farquhar, Chief Executive Officer at HeartFlow.

Coronary Artery Disease 59

Coronary Artery Disease Chest Pain Plaque Technology 59